Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Plus Therapeutics Analyst Ratings and Price Targets | NASDAQ:PSTV | Benzinga
Plus Therapeutics Inc has a consensus price target of $10.63 based on the ratings of 5 analysts. The high is $20 issued by Ascendiant Capital on April 21, 2025. The low is $5 issued by JonesTrading on October 7, 2022. The 3 most-recent analyst ratings were released by Ascendiant Capital, HC Wainwright & Co., and D. Boral Capital on April 21, 2025, March 28, 2025, and March 28, 2025, respectively. With an average price target of $11.5 between Ascendiant Capital, HC Wainwright & Co., and D. Boral Capital, there's an implied 3519.77% upside for Plus Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Ascendiant Capital
HC Wainwright & Co.
Maxim Group
JonesTrading
1calculated from analyst ratings
Analyst Ratings for Plus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/05/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert43% | — | Downgrade | Buy → Hold | Get Alert |
| 04/21/2025 | Buy Now | 6195.25% | Ascendiant Capital | Edward Woo60% | $19 → $20 | Maintains | Buy | Get Alert |
| 03/28/2025 | Buy Now | 1631.19% | HC Wainwright & Co. | Sean Lee65% | $8 → $5.5 | Maintains | Buy | Get Alert |
| 03/28/2025 | Buy Now | 2732.86% | D. Boral Capital | Jason Kolbert43% | $9 → $9 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 2732.86% | D. Boral Capital | Jason Kolbert43% | $9 → $9 | Maintains | Buy | Get Alert |
| 03/17/2025 | Buy Now | 2732.86% | D. Boral Capital | Jason Kolbert43% | → $9 | Initiates | → Buy | Get Alert |
| 12/09/2024 | Buy Now | 5880.48% | Ascendiant Capital | Edward Woo60% | $20 → $19 | Maintains | Buy | Get Alert |
| 11/26/2024 | Buy Now | 2418.1% | HC Wainwright & Co. | Sean Lee65% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 2418.1% | HC Wainwright & Co. | Sean Lee65% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 6195.25% | Ascendiant Capital | Edward Woo60% | $21 → $20 | Maintains | Buy | Get Alert |
| 08/16/2024 | Buy Now | 2418.1% | HC Wainwright & Co. | Sean Lee65% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 2418.1% | HC Wainwright & Co. | Sean Lee65% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 2418.1% | HC Wainwright & Co. | Sean Lee65% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 2418.1% | HC Wainwright & Co. | Sean Lee65% | $3.5 → $8 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | 3677.15% | Maxim Group | Jason McCarthy43% | $30 → $12 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | 1001.67% | HC Wainwright & Co. | Sean Lee65% | → $3.5 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 1001.67% | HC Wainwright & Co. | Sean Lee65% | → $3.5 | Reiterates | → Buy | Get Alert |
| 10/07/2022 | Buy Now | 1473.81% | JonesTrading | Justin Walsh39% | → $5 | Initiates | → Buy | Get Alert |
| 07/22/2022 | Buy Now | 1001.67% | HC Wainwright & Co. | Sean Lee65% | $7 → $3.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Plus Therapeutics (PSTV) stock?
The latest price target for Plus Therapeutics (NASDAQ:PSTV) was reported by D. Boral Capital on May 5, 2025. The analyst firm set a price target for $0.00 expecting PSTV to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Plus Therapeutics (PSTV)?
The latest analyst rating for Plus Therapeutics (NASDAQ:PSTV) was provided by D. Boral Capital, and Plus Therapeutics downgraded their hold rating.
When was the last upgrade for Plus Therapeutics (PSTV)?
There is no last upgrade for Plus Therapeutics
When was the last downgrade for Plus Therapeutics (PSTV)?
The last downgrade for Plus Therapeutics Inc happened on May 5, 2025 when D. Boral Capital changed their price target from N/A to N/A for Plus Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Plus Therapeutics (PSTV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Plus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Plus Therapeutics was filed on May 5, 2025 so you should expect the next rating to be made available sometime around May 5, 2026.
Is the Analyst Rating Plus Therapeutics (PSTV) correct?
While ratings are subjective and will change, the latest Plus Therapeutics (PSTV) rating was a downgraded with a price target of $0.00 to $0.00. The current price Plus Therapeutics (PSTV) is trading at is $0.32, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
